Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study

This real-world French study is the first switch/add-on study in mixed phenotypes of ATTRv. It highlights the potential benefits of early switching/adding of RNAi in patients with insufficient cardiac response under tafamidis.

Authors

Institutions

Publication Details

Journal
Archives of cardiovascular diseases
Published
2026-02-01
DOI
https://doi.org/10.1016/j.acvd.2025.11.014
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study

Bérengère Bachelet, Mounira Kharoubi, A. Fraix, Olivier Huttin et al.
Archives of cardiovascular diseases
Amyloidosis: Diagnosis, Treatment, Outcomes
article

Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study

Bérengère Bachelet, Mounira Kharoubi, A. Fraix, Olivier Huttin, Claire Huang Lucas, Patricia Réant, François Roubille, Antoine Jobbe Duval, E Donal, Olivier Lairez, Gilbert Habib, Thibaud Damy, Marie Arnal, Maud Michaud
article en

Abstract

This real-world French study is the first switch/add-on study in mixed phenotypes of ATTRv. It highlights the potential benefits of early switching/adding of RNAi in patients with insufficient cardiac response under tafamidis.

Archives of cardiovascular diseases
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), Université Toulouse III - Paul Sabatier (FR), Université de Bordeaux (FR), Inserm (FR), Lyon College (US), Université Paris-Est Créteil (FR), Université de Montpellier (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Centre Hospitalier Universitaire de Toulouse (FR), Physiologie et Médecine Expérimentale du Coeur et des Muscles (FR), Centre Hospitalier Universitaire de Montpellier (FR), Assistance Publique – Hôpitaux de Paris (FR), Centre Hospitalier Régional et Universitaire de Nancy (FR), Hospices Civils de Lyon (FR), Bordeaux Population Health (FR), Amyloidosis Foundation (US), Centre d'Investigation Clinique de Nantes (FR), Hôpitaux Universitaires Henri-Mondor (FR), Institut du Thorax (FR), Centre Hospitalier Universitaire de Rennes (FR), Institut Mondor de Recherche Biomédicale (FR), Hôpital de la Timone (FR), Université de Rennes (FR), Nantes Université (FR)
Alnylam Pharmaceuticals
Partnerships for the goals
Openalex Percentile: Top 61%
Amyloidosis: Diagnosis, Treatment, Outcomes
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.